Ipsen Biopharmaceuticals Inc. is the North American affiliate of Ipsen, a mid-size global specialty biopharmaceuticals leader in rare and orphan diseases in the areas of oncology, neuroscience and endocrinology.
Our ambition for patients, their families, healthcare providers and researchers goes beyond the life cycle of one therapeutic option – it is built on establishing a profound understanding of all aspects of the patient journey. We believe this approach based on concentrating our research, medical and commercial efforts will allow us to better understand the disease, patient needs, and potential areas for innovation. As a result of our efforts, we are a trusted and knowledgeable partner.
An example of this concentration of effort and expertise is our recent acquisition of Octreopharm Biosciences GmbH, a clinical development biopharmaceutical company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. Octroepharm is developing novel “theranostics” which represent investigational approaches to potentially improving the diagnosis and treatment of neuroendocrine tumors (NETs). This capability compliments Ipsen’s existing commercial and medical expertise in this therapeutic area as well as our strong research capabilities in the area of peptides. More recently, Ipsen also announced a worldwide licensing agreement with 3B Pharmaceuticals GmbH for the development of radiopharmaceuticals in niche oncology uses. This capability complements Octreopharm’s expertise. We are continuing to actively seek new partnerships and business development opportunities to expand our presence in oncology and in NET.
In neuroscience, we are also expanding our presence with a focus on the treatment of spasticity. Ipsen and Canbex Therapeutics recently announced an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead investigational candidate for the treatment of spasticity in adults with multiple sclerosis (MS), known as VSN16R. This agreement builds on our existing expertise in the area of spasticity research and is a strong indication of our commitment to the further development of treatments for this debilitating condition. Neuroscience, and spasticity in particular, are areas where Ipsen is pursuing business development opportunities that can support our growth.
Our endocrinology strategy has been focused on rare diseases. Our current presence in the areas of acromegaly and severe primary IGF-1 deficiency in children are examples of our commitment to advancing treatment in underserved orphan drug populations. We believe that this approach allows us to build strong relationships with patients, their treating physicians and leading researchers in niche uses.
At Ipsen Biopharmaceuticals, our commitment is to develop and deliver innovative therapies to treat serious illnesses and by doing so we will provide hope for patients, families and health care providers. We continuously transform ourselves with the goal of becoming one of the top performing biopharmaceutical companies in the U.S. and Canada.